Antibody immunosuppressive therapy in solid-organ transplant: Part I.
Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential benefits of the therapy.
Stanford School of Medicine, Palo Alto, CA, USA.
Nadim
N
Mahmud
Dusko
D
Klipa
Nasimul
N
Ahsan
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000209:etiology / Q000517:prevention & control; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control; D016377:Organ Transplantation
D000911:Antibodies, Monoclonal